KATARZYNA ANNA JACHIMOWSKA DO
Prescription History 1619534310
Family Medicine in Feasterville Trevose, PA

NPI Status: Active since May 29, 2019

Contact Information

1665 BUSTLETON PIKE
FEASTERVILLE TREVOSE, PA
ZIP 19053
Phone: (215) 355-9770

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for KATARZYNA ANNA JACHIMOWSKA DO, an active Family Medicine specialist practicing in Feasterville Trevose, PA. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 18 documented patient claims. Among these therapy options, the most frequently utilized medication is Lantus Solostar, which accounts for 18 claims alone.

Medication Index

No matching medications currently found on file.

Lantus Solostar

Generic Formulation: Insulin Glargine,hum.Rec.AnlogSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 18
30-Day Fills 26.7
Days Supply 770
PA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills74.7
Peer Average Days Supply2,103
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.1% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,997.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$555.44

State Avg Cost Per Claim

$552.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.

Therapeutic Applications

Insulin glargine is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin glargine is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin glargine may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs. This monograph is about the following insulin glargine products: insulin glargine, insulin glargine-yfgn.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like KATARZYNA ANNA JACHIMOWSKA DO provides transparency into local medical care patterns within Feasterville Trevose, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.